TransMedics Group, Inc. (NASDAQ:TMDX) CEO Waleed H. Hassanein Sells 8,625 Shares

TransMedics Group, Inc. (NASDAQ:TMDX) CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the transaction, the chief executive officer now directly owns 61,643 shares in the company, valued at approximately $9,457,269.06. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

TransMedics Group Stock Up 3.2 %

TransMedics Group stock traded up $4.87 during mid-day trading on Tuesday, hitting $156.08. The company’s stock had a trading volume of 821,976 shares, compared to its average volume of 773,351. The company has a market cap of $5.21 billion, a PE ratio of -459.06 and a beta of 1.99. TransMedics Group, Inc. has a 52-week low of $36.42 and a 52-week high of $177.37. The company has a debt-to-equity ratio of 2.67, a current ratio of 9.37 and a quick ratio of 8.48. The firm’s 50 day moving average is $154.40 and its 200 day moving average is $127.98.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings results on Wednesday, July 31st. The company reported $0.35 EPS for the quarter, beating the consensus estimate of $0.21 by $0.14. The business had revenue of $114.30 million for the quarter, compared to analysts’ expectations of $98.84 million. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. TransMedics Group’s revenue was up 117.7% on a year-over-year basis. During the same period in the previous year, the company posted ($0.03) EPS. On average, analysts anticipate that TransMedics Group, Inc. will post 1.23 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on TMDX. TD Cowen raised their price objective on shares of TransMedics Group from $130.00 to $175.00 and gave the company a “buy” rating in a research note on Friday, June 7th. Needham & Company LLC assumed coverage on shares of TransMedics Group in a report on Wednesday, August 21st. They set a “buy” rating and a $208.00 target price for the company. Stephens increased their price objective on TransMedics Group from $151.00 to $178.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. Piper Sandler raised their price objective on TransMedics Group from $170.00 to $180.00 and gave the stock an “overweight” rating in a research note on Thursday, August 1st. Finally, Canaccord Genuity Group boosted their target price on TransMedics Group from $117.00 to $169.00 and gave the stock a “buy” rating in a research report on Thursday, August 1st. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, TransMedics Group has a consensus rating of “Moderate Buy” and an average price target of $171.44.

Hedge Funds Weigh In On TransMedics Group

Hedge funds have recently added to or reduced their stakes in the company. Sanctuary Advisors LLC bought a new stake in TransMedics Group in the second quarter worth approximately $372,000. Teachers Retirement System of The State of Kentucky acquired a new position in TransMedics Group during the second quarter worth $420,000. NewEdge Advisors LLC raised its holdings in TransMedics Group by 26.0% during the second quarter. NewEdge Advisors LLC now owns 10,372 shares of the company’s stock valued at $1,562,000 after buying an additional 2,140 shares in the last quarter. Creative Planning lifted its position in shares of TransMedics Group by 78.3% in the second quarter. Creative Planning now owns 9,173 shares of the company’s stock worth $1,382,000 after buying an additional 4,027 shares during the last quarter. Finally, Algert Global LLC bought a new stake in shares of TransMedics Group during the 2nd quarter worth about $2,685,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.